Mathieu Spaas retweeted
Words of wisdom on the NIVES trial: SBRT + nivo in mRCC. Our take on what is next and abandon the quest for the "abscopal" effect. @MathieuSpaas @NoraSundahl @_ShankarSiva @rweichselbaum
bit.ly/3oOQXDq
Mathieu Spaas retweeted
Really pleased to bring this to fruition. Collaboration between multiple partners to shed insights on combination immunotherapy and radiotherapy, so as to guide best combination therapies! #RTimmuno #checkpoint blockade #precisionRT @ASTRO_org redjournal.org/article/S0360…
Mathieu Spaas retweeted
Review: Characterisation & classification of #oligometastatic disease: a @ESTRO_RT and @EORTC consensus recommendation thelancet.com/journals/lanon…
Mathieu Spaas retweeted
Great news. Let's include as many as possible in the CHEERS trial when starting anti PD(L)-1. Maybe we can further improve the outcome! @JulesBordet #OncoAlert
#OncoAlert #ImmunoOnc Nivolumab treatment was associated with long-term survival in a subset of heavily pretreated patients with advanced melanoma, RCC, or NSCLC ja.ma/2TeMn10